1374239-83-4

Basic information

• Product Name: 1-(1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone
• Synonyms: 1-(1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone
• CAS NO: 1374239-83-4
• Molecular Weight: 446.339
• Mol File: 1374239-83-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone(1374239-83-4)
• EPA Substance Registry System: 1-(1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone(1374239-83-4)

Safety Data

• Hazardous Substances Data: 1374239-83-4(Hazardous Substances Data)

Upstream product

• 1374243-45-4 C₂₆H₃₅Cl₂N₇O₂Si 
• 1374243-44-3 tert-butyl 6-(2-(3,5-dichlorophenylamino)acetyl)octahydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 1095822-25-5 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-d]pyrimidine 
• 1374243-70-5 C₁₅H₁₉Cl₂N₃O 
• 169750-88-3 tert-butyl 2,3,3a,4,5,6,7,7a-octahydropyrrolo[2,3-c]pyridine-1-carboxylate 
• 370880-82-3 tert-butyl 1H-pyrrolo [2,3-c]pyridine-1-carboxylate 
• 271-29-4 6-azaindole 

Relevant articles and documents

HETEROCYCLIC TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.